Name: Advances in Tardive Dyskinesia: Valbenazine, VMAT2 Inhibition, and the Future of Care by First Report Managed Care
Duration: 21 min 38 s
Description: A guest expert discusses his decades of schizophrenia research and highlights how valbenazine has transformed the treatment of tardive dyskinesia with rapid, dramatic, and well-tolerated results.

A guest expert discusses the role of technology in shifting to proactive health care, emphasizing the relationship between data, AI, and personalized care in improving outcomes and reducing costs.

The Future of Remote Patient Monitoring: Overcoming Challenges and Embracing Personalized Care

Time-Limited Therapy in CLL: A Value-Based Approach to Modern Oncology

A guest expert discusses his decades of schizophrenia research and highlights how valbenazine has transformed the treatment of tardive dyskinesia with rapid, dramatic, and well-tolerated results.

Advances in Tardive Dyskinesia: Valbenazine, VMAT2 Inhibition, and the Future of Care

First Report Managed Care

Related tracks